companiesCompany
Kyowa Kirin
Kyowa Kirin is a Japanese biopharmaceutical company whose oncology products include mogamulizumab (Poteligeo) for cutaneous T-cell lymphoma and toremifene (Fareston) for metastatic breast cancer.
Overview
Kyowa Kirin, part of the Kirin group, developed the anti-CCR4 antibody mogamulizumab and markets Fareston (toremifene) in the US; it also sells Crysvita (burosumab) and G-CSF products in Japan.
Headquarters
Tokyo, JP
Scorecard
All companies#111of 680 companies, score 23
- approved products +6
- targets +2
- modalities +2
- regions +2
- registry trials +11
1 approved, 0 in phase 3, 0 earlier, 1 targets, 32 registry studies. Formula on the scorecards page.
Type
pharma · 4151.T
Stage
Public
Website